Ambroxol Geiser Lakrits: Uses, Dosage & Side Effects
A liquorice-flavored mucolytic lozenge used to relieve productive cough and soothe sore throat pain
Ambroxol Geiser Lakrits is a liquorice-flavored lozenge containing 20 mg of ambroxol hydrochloride, a well-established mucolytic agent used to relieve symptoms of productive (wet) cough associated with acute and chronic respiratory conditions. Ambroxol works by thinning thick, sticky mucus in the airways, making it easier to cough up and clear from the lungs. In lozenge form, it also provides local soothing relief for sore throat pain through a mild local anesthetic effect on the oropharyngeal mucosa. Ambroxol is a metabolite of bromhexine and has been used in clinical practice for over 50 years, with a well-documented safety profile.
Quick Facts: Ambroxol Geiser Lakrits
Key Takeaways
- Ambroxol Geiser Lakrits is a liquorice-flavored lozenge containing 20 mg of ambroxol hydrochloride, used to relieve productive cough by thinning and loosening mucus in the airways.
- The lozenge form also provides local soothing and mild anesthetic relief for sore throat pain, making it useful for upper respiratory tract infections.
- Adults and adolescents over 12 years can take up to 3 lozenges per day; treatment should generally not exceed 4–5 days without consulting a healthcare professional.
- Ambroxol should not be used together with cough suppressants (antitussives), as this combination may lead to mucus accumulation in the airways.
- Serious side effects are very rare; however, severe allergic reactions and skin reactions (Stevens-Johnson syndrome) have been reported in isolated cases – discontinue use and seek medical help immediately if these occur.
What Is Ambroxol Geiser Lakrits and What Is It Used For?
Ambroxol Geiser Lakrits belongs to a class of medications known as mucolytic agents (also called secretolytics or expectorants). The active ingredient, ambroxol hydrochloride, is a benzylamine derivative and a metabolite of the older mucolytic drug bromhexine. Ambroxol has been used extensively in clinical practice since the 1970s and is one of the most widely used mucolytics worldwide. It is available in numerous formulations including tablets, syrups, inhalation solutions, and – as in this product – lozenges designed for oropharyngeal dissolution.
The medication works through several complementary mechanisms of action. First, ambroxol stimulates the serous cells of the submucosal glands in the bronchial epithelium, increasing the production of thin, watery secretions. This dilutes the thick, viscous mucus that accumulates during respiratory infections and inflammatory conditions. Second, ambroxol activates hydrolytic enzymes (lysosomal enzymes) within the Clara cells and type II pneumocytes of the lung, which break down the mucopolysaccharide fibers and glycoprotein structures that give pathological mucus its abnormal thickness and stickiness. The net result is a reduction in mucus viscosity, making it significantly easier to clear from the airways through the body's natural mucociliary clearance mechanisms.
In addition to its mucolytic properties, ambroxol has several other pharmacological effects that contribute to its therapeutic benefit. It stimulates the production and release of pulmonary surfactant – the phospholipid-rich substance that lines the alveoli and maintains their stability during breathing. Surfactant deficiency or dysfunction is associated with various respiratory conditions, and the surfactant-stimulating effect of ambroxol may help improve lung function, particularly in patients with chronic respiratory disease. Ambroxol also enhances ciliary beat frequency, meaning the microscopic hair-like structures (cilia) that line the airways move more effectively to transport mucus upward and out of the lungs.
When taken as a lozenge, ambroxol provides an additional local effect in the throat. Research has demonstrated that ambroxol possesses local anesthetic properties through its ability to block sodium channels in the oropharyngeal mucosa. This sodium channel blockade is similar in mechanism to that of traditional local anesthetics such as lidocaine, though considerably milder. The result is a temporary numbing and soothing effect on sore throat pain, which makes the lozenge formulation particularly useful for patients who have both a productive cough and throat discomfort – a common combination during upper respiratory tract infections.
Ambroxol Geiser Lakrits is indicated for the symptomatic treatment of the following conditions:
- Productive (wet) cough: Cough associated with excessive or abnormally thick mucus production, as seen in acute upper and lower respiratory tract infections (common cold, influenza, bronchitis, tracheobronchitis).
- Acute bronchitis: Inflammation of the bronchial airways with increased mucus production, typically caused by viral infection.
- Chronic bronchitis and COPD exacerbations: As adjunctive therapy to improve mucus clearance during acute exacerbations of chronic obstructive pulmonary disease.
- Sore throat relief: The lozenge provides local soothing and mild anesthetic relief for pain associated with pharyngitis and laryngitis.
- Post-nasal drip: To thin and facilitate clearance of thick mucus draining from the sinuses into the throat.
It is important to note that ambroxol treats the symptoms of respiratory conditions (mucus and cough) but does not treat the underlying cause. If your cough is caused by a bacterial infection, your doctor may prescribe antibiotics alongside ambroxol. If symptoms persist beyond 4–5 days, worsen, or are accompanied by high fever, blood-stained mucus, or difficulty breathing, seek medical advice promptly, as these may indicate a more serious condition requiring different treatment.
Ambroxol is designed for productive (wet) cough where mucus needs to be cleared from the airways. It should not be used for dry, irritating cough where no mucus is present, as promoting expectoration in the absence of mucus production offers no benefit. If you are unsure whether your cough is productive or dry, consult your doctor or pharmacist for advice on the most appropriate treatment.
What Should You Know Before Taking Ambroxol Geiser Lakrits?
Contraindications
There are specific situations in which Ambroxol Geiser Lakrits should not be used. Understanding these contraindications is essential for safe self-medication or prescribed use of this product.
- Hypersensitivity: Do not take this product if you have a known allergy (hypersensitivity) to ambroxol hydrochloride, bromhexine, or any of the inactive ingredients (excipients) in the lozenge, including liquorice extract or any flavoring or coloring agents. Allergic reactions to ambroxol are uncommon but can include skin rash, urticaria (hives), and in very rare cases, anaphylaxis.
- Children under 12 years: This lozenge formulation (20 mg) is not intended for use in children under 12 years of age. Children in this age group may be at risk of choking on lozenges, and lower-strength liquid formulations are more appropriate for pediatric patients.
- Hereditary fructose intolerance: Some ambroxol lozenge formulations may contain sorbitol or other sugar alcohols. Patients with rare hereditary fructose intolerance should check the excipient list and consult their pharmacist before use.
Warnings and Precautions
In very rare cases, severe skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in temporal association with the use of mucolytic agents including ambroxol. These are serious, potentially life-threatening conditions. If you develop a new skin rash, blistering of the skin or mucous membranes, mouth ulcers, or fever during treatment with ambroxol, stop taking the medication immediately and seek urgent medical attention.
You should consult your doctor before taking Ambroxol Geiser Lakrits if any of the following conditions apply to you:
- Impaired mucociliary clearance: In patients with conditions that significantly impair the cough reflex or mucociliary transport (such as severe neuromuscular disease or primary ciliary dyskinesia), the increased volume of liquefied secretions produced by ambroxol may potentially overwhelm the clearing mechanisms. Use only under medical supervision in such patients.
- Impaired kidney function: Ambroxol and its metabolites are excreted primarily through the kidneys. In patients with significant renal impairment, metabolites may accumulate. Use with caution and consider dose reduction or extended dosing intervals in patients with severe kidney disease.
- Impaired liver function: Ambroxol undergoes extensive hepatic metabolism. In patients with severe liver disease, clearance may be reduced. Use with caution and under medical supervision.
- History of peptic ulcer disease: Some early animal studies suggested a potential for ambroxol to affect the gastric mucosal barrier, although this has not been confirmed as clinically significant in humans at standard doses. Patients with active or recent gastric or duodenal ulcers should use ambroxol with caution.
- Previous severe drug reactions: If you have a history of Stevens-Johnson syndrome or toxic epidermal necrolysis with any medication, discuss with your doctor before taking ambroxol, as there may be an increased susceptibility to severe skin reactions.
- Excessive liquorice consumption: The liquorice flavoring in this product contains glycyrrhizin. In large quantities, glycyrrhizin can cause pseudoaldosteronism, leading to potassium depletion, sodium retention, and elevated blood pressure. At the amounts present in a few lozenges per day, this is extremely unlikely to be clinically significant, but patients who consume large amounts of liquorice from other dietary sources or who have hypertension or hypokalemia should be aware.
If symptoms persist for more than 4–5 days without improvement, or if they worsen during treatment, do not continue self-treatment. Consult a doctor, as persistent or worsening cough may indicate a more serious underlying condition such as pneumonia, asthma, or other respiratory disease requiring specific treatment.
Pregnancy and Breastfeeding
Ambroxol should be avoided during pregnancy, particularly during the first trimester, unless the potential benefit clearly justifies the potential risk. Although extensive animal reproductive studies have not demonstrated direct harmful effects on embryonic or fetal development, human clinical data on the use of ambroxol during pregnancy is limited. The European Medicines Agency (EMA) advises caution, and most national regulatory authorities recommend that ambroxol should only be used during pregnancy when specifically advised by a healthcare professional.
Ambroxol is excreted into human breast milk in small amounts. While adverse effects on the nursing infant have not been reported at therapeutic doses, a cautious approach is recommended. Breastfeeding women should consult their doctor or pharmacist before using Ambroxol Geiser Lakrits, and the product should be used only if the expected benefit to the mother outweighs any potential risk to the infant.
If you are pregnant, planning to become pregnant, or breastfeeding, always discuss with your healthcare provider before starting any new medication, including over-the-counter or pharmacy-only products like ambroxol lozenges.
Driving and Operating Machinery
Ambroxol Geiser Lakrits has no known effect on the ability to drive or operate machinery. At standard therapeutic doses, ambroxol does not cause drowsiness, dizziness, or impairment of cognitive function. However, if you experience any unexpected side effects that affect your concentration or alertness, refrain from driving or operating machinery until the effects have resolved.
How Does Ambroxol Geiser Lakrits Interact with Other Drugs?
Ambroxol has a relatively favorable drug interaction profile compared to many other medications. However, several interactions are worth noting, particularly the important contraindication against combining mucolytics with cough suppressants. Always inform your doctor, pharmacist, or nurse about all medications you are currently taking, including prescription drugs, over-the-counter remedies, herbal supplements, and homeopathic preparations.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Antitussives (codeine, dextromethorphan, noscapine, pholcodine) | Cough suppressants reduce the cough reflex, which is needed to clear the increased volume of liquefied mucus produced by ambroxol. Concurrent use may lead to dangerous mucus retention and pooling in the airways. | Do not use ambroxol together with cough suppressants. If you have both a productive and an irritating cough component, consult your doctor for appropriate guidance rather than combining these medications yourself. |
Minor Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) | Ambroxol has been shown to increase the penetration and concentration of certain antibiotics in bronchial secretions and lung tissue. This is generally considered a beneficial interaction that may improve antibiotic efficacy in respiratory infections. | This interaction is typically therapeutic. Ambroxol is sometimes used deliberately alongside antibiotics for respiratory infections. No dose adjustment is usually required, but inform your doctor if you are taking both. |
| Other mucolytics or expectorants (acetylcysteine, guaifenesin, carbocisteine) | Combining multiple mucolytic agents may produce excessive liquefaction of bronchial secretions, potentially overwhelming mucociliary clearance capacity, particularly in debilitated or elderly patients. | Avoid combining multiple mucolytic medications unless specifically directed by your doctor. Using one mucolytic at the appropriate dose is generally sufficient. |
| Liquorice-containing products (herbal teas, confectionery, other supplements) | The liquorice flavoring in the lozenges contains glycyrrhizin. Combined with other dietary sources of glycyrrhizin, excessive intake may theoretically contribute to pseudoaldosteronism (potassium depletion, sodium retention, blood pressure elevation). | At normal dosing (up to 3 lozenges daily), the glycyrrhizin content is minimal. However, patients with hypertension, hypokalemia, or those taking digoxin or diuretics should moderate their total liquorice intake from all sources. |
One of the notable pharmacological properties of ambroxol is its ability to increase the concentration of antibiotics – particularly amoxicillin, cefuroxime, and erythromycin – in bronchopulmonary secretions. Clinical studies have demonstrated that when ambroxol is co-administered with these antibiotics, the antibiotic concentrations in sputum and bronchial mucosa increase by 20–40% compared to the antibiotic alone. This synergistic effect is thought to result from ambroxol's ability to improve the permeability of the bronchial mucosa and enhance the distribution of antibiotic molecules into respiratory tract tissues. This property has led to ambroxol being used as a deliberate adjunct therapy in the treatment of lower respiratory tract infections in some European countries.
What Is the Correct Dosage of Ambroxol Geiser Lakrits?
The following dosage information applies specifically to Ambroxol Geiser Lakrits 20 mg lozenges. Dosing recommendations are based on EMA guidelines, national regulatory authority SmPCs, and established clinical practice. Always follow the instructions provided by your doctor or pharmacist, as individual dosing may vary based on your specific clinical situation.
Adults and Adolescents (Over 12 Years)
Standard Lozenge Dosing
Dose: 1 lozenge (20 mg ambroxol hydrochloride) up to 3 times daily
Maximum daily dose: 3 lozenges (60 mg) per 24 hours
Administration: Allow the lozenge to dissolve slowly in the mouth. Do not chew, crush, or swallow whole. Optimal efficacy requires slow dissolution to allow local absorption through the oropharyngeal mucosa.
Timing: Lozenges may be taken with or without food. Space doses evenly throughout the day, approximately every 6–8 hours.
Duration: Do not use for more than 4–5 consecutive days without consulting a healthcare professional. If symptoms persist beyond this period, seek medical advice.
| Indication | Dose | Duration |
|---|---|---|
| Acute productive cough (common cold, bronchitis) | 1 lozenge (20 mg) up to 3 times daily | 4–5 days (without medical advice) |
| Acute sore throat | 1 lozenge (20 mg) up to 3 times daily | 3–5 days |
| Chronic bronchitis / COPD exacerbation (as adjunct) | 1 lozenge (20 mg) 2–3 times daily | As directed by physician |
Children
Pediatric Use
Children under 12 years: This lozenge formulation (20 mg) is not recommended for children under 12 years of age due to the risk of choking and the difficulty of ensuring slow dissolution in younger children.
Alternative formulations for children: Ambroxol is available in child-appropriate formulations such as oral syrup (typically 15 mg/5 ml or 30 mg/5 ml) and oral drops. Children aged 2–5 years typically receive 7.5 mg (half a teaspoon of 15 mg/5 ml syrup) two to three times daily. Children aged 6–12 years typically receive 15 mg two to three times daily. Always consult a pediatrician for appropriate dosing in children.
Elderly Patients
No specific dose adjustment is routinely required for elderly patients with normal organ function. However, elderly individuals are more likely to have impaired kidney or liver function, which may affect the elimination of ambroxol and its metabolites. In elderly patients with significant renal or hepatic impairment, consider using a lower dose or extending the interval between doses. Elderly patients may also have a diminished cough reflex, which means the increased mucus liquefaction produced by ambroxol could potentially lead to mucus retention. Use under medical supervision in frail elderly patients.
Missed Dose
If you forget to take a lozenge at the scheduled time, take it as soon as you remember, unless it is nearly time for your next dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take two lozenges at the same time or take extra lozenges to make up for a missed dose. Because ambroxol lozenges are used for symptom relief rather than to maintain a constant blood level, occasional missed doses are unlikely to significantly affect treatment outcomes.
Overdose
If you suspect an ambroxol overdose or if a child has accidentally consumed multiple lozenges, contact your local emergency services or poison control center immediately.
No specific reports of serious ambroxol overdose have been documented in clinical literature. Based on the pharmacological profile of ambroxol, overdose symptoms are expected to be an extension of known side effects and may include nausea, vomiting, diarrhea, abdominal discomfort, and transient restlessness. In significant overdose, hypersalivation and excessive bronchial secretion could theoretically occur. Treatment is symptomatic and supportive, with attention to maintaining adequate hydration. Gastric lavage or induced vomiting is generally only indicated if very large amounts have been ingested within the preceding 1–2 hours. There is no specific antidote for ambroxol. The relatively wide therapeutic index of ambroxol means that serious toxicity from overdose is unlikely in most cases.
What Are the Side Effects of Ambroxol Geiser Lakrits?
Like all medicines, Ambroxol Geiser Lakrits can cause side effects, although not everyone who takes it will experience them. The majority of reported side effects are mild, transient, and resolve without specific treatment once the medication is stopped or the course is completed. The following classification is based on data from regulatory authorities including the EMA, post-marketing surveillance reports, and published clinical studies.
Common
- Dysgeusia (altered taste): Temporary change in taste perception, typically manifesting as a metallic or unusual taste in the mouth; resolves after discontinuation
- Oropharyngeal hypoesthesia (mouth/throat numbness): Temporary numbness or reduced sensation in the mouth and throat due to the local anesthetic effect of ambroxol; this is a pharmacological effect rather than a true side effect and resolves within 30–60 minutes
- Nausea: Usually mild; may be reduced by taking the lozenge after a meal
Uncommon
- Vomiting: Occasional, usually mild and self-limiting
- Diarrhea: Loose stools, typically mild
- Abdominal pain: Mild stomach discomfort or cramping
- Dry mouth: Temporary sensation of oral dryness
- Throat dryness: Paradoxical dryness of the pharyngeal mucosa
Rare
- Skin rash: Generalized or localized skin eruption
- Urticaria (hives): Raised, itchy welts on the skin; may indicate an allergic reaction
- Pruritus (itching): Generalized or localized itching without visible skin changes
- Dyspepsia (indigestion): Upper abdominal discomfort, bloating, or heartburn
Very Rare
- Anaphylaxis: Severe, life-threatening allergic reaction with rapid onset of breathing difficulty, swelling of face/throat, and circulatory collapse; requires immediate emergency treatment with epinephrine (adrenaline)
- Angioedema: Deep tissue swelling of the face, lips, tongue, or throat that may impair breathing or swallowing
- Stevens-Johnson syndrome (SJS): Severe skin reaction characterized by painful blistering and peeling of the skin, mouth sores, and flu-like symptoms; requires immediate hospital care
- Toxic epidermal necrolysis (TEN): The most severe form of drug-induced skin reaction with widespread skin detachment; a medical emergency
- Acute generalized exanthematous pustulosis (AGEP): Widespread pustular skin eruption with fever
Stop taking Ambroxol Geiser Lakrits and seek emergency medical care immediately if you experience: swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; widespread skin rash with blistering or peeling; severe chest tightness or wheezing; mouth ulcers or sores on mucous membranes; high fever with skin changes. These symptoms may indicate a serious allergic or skin reaction requiring urgent treatment.
The local anesthetic effect of ambroxol on the oropharyngeal mucosa (temporary mouth/throat numbness) is an expected pharmacological property of the lozenge formulation and should not be confused with an allergic reaction. This numbness is dose-dependent, typically lasts 30–60 minutes after the lozenge has dissolved, and resolves completely without any intervention. During this period of reduced sensation, take care when eating or drinking hot beverages to avoid accidental injury to the mouth or throat.
If you experience any side effects, including those not listed here, you can report them to your national pharmacovigilance authority (such as the MHRA Yellow Card scheme in the UK, the EMA EudraVigilance system in Europe, or the FDA MedWatch program in the US). Reporting side effects helps to continuously monitor the safety of medicines and identify previously unrecognized adverse reactions.
How Should You Store Ambroxol Geiser Lakrits?
Proper storage of Ambroxol Geiser Lakrits lozenges is important to ensure the medication remains effective and safe throughout its shelf life. Incorrect storage can lead to degradation of the active ingredient or changes in the physical properties of the lozenge (such as softening, discoloration, or altered dissolution characteristics).
- Temperature: Store below 25°C (77°F) at room temperature. Do not refrigerate or freeze. Avoid storing in locations subject to temperature extremes, such as in a car during summer or near radiators or heating sources.
- Moisture protection: Keep the lozenges in their original blister packaging until you are ready to take one. Ambroxol lozenges are hygroscopic (absorb moisture from the air), and exposure to humidity can affect their consistency and dissolution properties. Do not store in bathrooms or other high-humidity environments.
- Light protection: Protect from direct sunlight and strong artificial light. Store in the original outer carton when not in use.
- Child safety: Keep out of the sight and reach of children. The liquorice flavor and lozenge format may be attractive to children, and accidental ingestion of multiple lozenges could pose a choking hazard or lead to overdose symptoms.
- Expiry date: Do not use after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month. Inspect lozenges before use – if they appear discolored, have an unusual odor, or are damaged or broken, do not use them.
- Disposal: Do not dispose of unused or expired lozenges via household waste or down drains or toilets. Return them to your local pharmacy for environmentally safe disposal in accordance with local regulations.
What Does Ambroxol Geiser Lakrits Contain?
Each Ambroxol Geiser Lakrits lozenge contains the following components:
Active Ingredient
Ambroxol hydrochloride 20 mg: The pharmacologically active component responsible for the mucolytic (mucus-thinning) and local anesthetic effects. Ambroxol hydrochloride is a white to slightly yellowish crystalline powder with a molecular weight of 414.6 g/mol. It is a metabolite of bromhexine and belongs to the class of benzylamine-derived mucolytic agents. Each lozenge delivers exactly 20 mg of ambroxol hydrochloride, equivalent to approximately 16.4 mg of ambroxol base.
Excipients (Inactive Ingredients)
The exact excipient composition may vary slightly between different batches and manufacturers, but Ambroxol Geiser Lakrits lozenges typically contain the following inactive ingredients:
- Liquorice root extract (Glycyrrhiza glabra): Provides the characteristic liquorice flavor. Contains glycyrrhizin, a natural sweetener approximately 50 times sweeter than sucrose. The amount per lozenge is minimal and not expected to cause pharmacological effects at recommended dosages.
- Sorbitol (E420): A sugar alcohol used as a sweetener and bulking agent. Patients with rare hereditary fructose intolerance should note its presence.
- Acesulfame potassium (E950): A non-caloric artificial sweetener used to enhance palatability.
- Magnesium stearate: A lubricant used in the manufacturing process to prevent the lozenge from sticking to production equipment.
- Gum arabic (E414): A natural binding agent derived from acacia trees.
- Flavoring agents: Additional natural and/or artificial flavoring agents to complement the liquorice taste profile.
- Coloring agents: May include caramel color (E150) to provide the characteristic dark appearance.
If you have known allergies to any excipients, always check the specific product's patient information leaflet for the complete list of ingredients before use. The patient information leaflet enclosed in the product packaging provides the most up-to-date and product-specific list of excipients. Consult your pharmacist if you have any concerns about specific ingredients.
Ambroxol Geiser Lakrits lozenges are typically sugar-free, using sorbitol and acesulfame potassium as sweeteners instead of sucrose. This makes them suitable for patients with diabetes mellitus, although the caloric contribution of sorbitol (approximately 2.6 kcal/g) should be noted. The sugar-free formulation also means the lozenges are less likely to contribute to dental caries compared to sugar-containing lozenges.
Frequently Asked Questions About Ambroxol Geiser Lakrits
Ambroxol Geiser Lakrits is a liquorice-flavored lozenge containing 20 mg of ambroxol hydrochloride. It is primarily used for two purposes: (1) to relieve productive (wet) cough by thinning and loosening thick mucus in the airways, making it easier to cough up, and (2) to provide local soothing and mild anesthetic relief for sore throat pain. It is commonly used during upper respiratory tract infections such as the common cold, influenza, and acute bronchitis. The lozenge dissolves slowly in the mouth, allowing ambroxol to work both locally in the throat and systemically after absorption.
No, you should not take Ambroxol Geiser Lakrits together with cough suppressant (antitussive) medications such as codeine, dextromethorphan, noscapine, or pholcodine. Ambroxol is a mucolytic that works by thinning and loosening mucus so it can be coughed up more easily. Cough suppressants, on the other hand, reduce the cough reflex. If you suppress the cough while simultaneously producing thinner, more liquid mucus, the mucus may accumulate and pool in the airways, potentially worsening the respiratory condition and increasing the risk of secondary infection. If you have a cough with both productive and irritating components, consult your doctor for appropriate treatment guidance.
The temporary numbness you feel in your mouth and throat after taking an Ambroxol Geiser Lakrits lozenge is a normal and expected pharmacological effect, not a side effect or allergic reaction. Ambroxol has local anesthetic properties – it blocks sodium channels in the nerve endings of the oropharyngeal mucosa, similar in mechanism (though milder) to local anesthetics like lidocaine. This numbness typically lasts 30–60 minutes after the lozenge has fully dissolved and resolves completely on its own. This same property is what provides the sore throat pain relief. During the numbness period, be cautious when eating or drinking hot beverages to avoid accidentally biting your cheek or burning your mouth or throat.
Ambroxol should be avoided during pregnancy, especially during the first trimester, unless your doctor specifically advises you to take it. While animal studies have not shown harmful effects on the developing fetus, there is limited clinical data on the use of ambroxol in pregnant women, and a precautionary approach is recommended. Ambroxol is excreted in breast milk in small amounts. Although no adverse effects on nursing infants have been reported at therapeutic doses, breastfeeding mothers should consult their doctor or pharmacist before using the product. If you are pregnant, planning to become pregnant, or breastfeeding, always discuss medication use with your healthcare provider.
You should not use Ambroxol Geiser Lakrits for more than 4–5 consecutive days without consulting a healthcare professional. If your cough or sore throat symptoms persist beyond this period, worsen during treatment, or are accompanied by concerning symptoms such as high fever (above 38.5°C / 101.3°F), blood in your sputum, chest pain, significant difficulty breathing, or unintentional weight loss, you should see a doctor promptly. Persistent cough lasting more than 3 weeks should always be investigated by a healthcare professional, as it may indicate an underlying condition such as asthma, COPD, pneumonia, or other respiratory disease requiring specific diagnosis and treatment.
Ambroxol Geiser Lakrits 20 mg lozenges are not recommended for children under 12 years of age. The lozenge formulation poses a potential choking risk for younger children, and the 20 mg strength may not be appropriate for their body weight. For children who need ambroxol, child-friendly formulations are available, including oral syrups and drops with age-appropriate dosing. Children aged 2–5 years typically receive 7.5 mg two to three times daily, while children aged 6–12 years typically receive 15 mg two to three times daily. Always consult a pediatrician or pharmacist for guidance on the most appropriate ambroxol product and dose for your child's age and weight.
References
This article is based on current international medical guidelines, regulatory documents, and peer-reviewed research. All sources meet evidence level 1A standards.
- European Medicines Agency (EMA). Ambroxol and Bromhexine – Article 31 Referral – Assessment Report. EMA/PRAC; 2015. Comprehensive safety review covering severe cutaneous adverse reactions and updated product information for ambroxol-containing medicines.
- Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opinion on Drug Metabolism & Toxicology. 2008;4(8):1119-1129. doi:10.1517/17425255.4.8.1119
- Paleari D, Rossi GA, Nicolini G, Olivieri D. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opinion on Drug Discovery. 2011;6(11):1203-1214. doi:10.1517/17460441.2011.629646
- Klier K, Lehmann J. Effect of ambroxol on the concentration of amoxicillin in bronchial secretions and in plasma. Arzneimittelforschung. 1980;30(10):1665-1669.
- de Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A. An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome. Cough. 2012;8(1):1. doi:10.1186/1745-9974-8-1
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Reference for global pharmaceutical standards and essential medicine classification.
- Weiser T, Wilson N. Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na+ channels by the secretolytic ambroxol. Molecular Pharmacology. 2002;62(3):433-438. doi:10.1124/mol.62.3.433
- Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press; 2024. Evidence-based prescribing reference covering mucolytics and expectorants.
- National Institute for Health and Care Excellence (NICE). Cough (acute): antimicrobial prescribing. NICE Guideline NG120; 2019. Guidelines for the management of acute cough in primary care.
- Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. European Journal of Medical Research. 2008;13(12):557-562.
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology and respiratory medicine.
Content developed by iMedic's medical writing team based on current international guidelines (EMA, WHO, BNF, NICE) and peer-reviewed pharmacological research.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in clinical pharmacology and respiratory medicine.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.